{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:05:26Z","timestamp":1787231126585,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.rdc.2021.04.012","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T04:08:43Z","timestamp":1623298123000},"page":"513-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment Update in Systemic Lupus Erythematous"],"prefix":"10.1016","volume":"47","author":[{"given":"Alberta Y.","family":"Hoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2021.04.012_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/art.22641","article-title":"Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data","volume":"56","author":"Chakravarty","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.04.012_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2021.04.012_bib5","article-title":"The Asia Pacific League of Associations for Rheumatology (APLAR) consensus statements on the management of systemic lupus erythematosus","author":"Chi Chiu Mok","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.rdc.2021.04.012_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.04.012_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(19)30048-7","article-title":"Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.04.012_bib9","first-page":"E95","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus:","volume":"1","author":"Golder","year":"2019","journal-title":"a prospective validation study."},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13075-017-1451-5","article-title":"Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in caucasian patients with systemic lupus erythematosus","volume":"19","author":"Piga","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2017-211613","article-title":"Lupus low disease activity state is associated with a decrease in damage progression in caucasian patients with SLE, but overlaps with remission","volume":"77","author":"Zen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2021.04.012_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0961203319826693","article-title":"Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort","volume":"28","author":"Alarc\u00f3n","year":"2019","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib13","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2016-210382","article-title":"Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus","volume":"76","author":"Mok","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-017-1256-6","article-title":"Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study","volume":"19","author":"Golder","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.rdc.2021.04.012_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Supplement_5","key":"10.1016\/j.rdc.2021.04.012_bib16","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","article-title":"Treatment targets in SLE: remission and low disease activity state","volume":"59","author":"Golder","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2021.04.012_bib18","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","article-title":"Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action","volume":"50","author":"Buttgereit","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.04.012_bib20","first-page":"1","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","author":"Apostolopoulos","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/annrheumdis-2020-217566","article-title":"Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/acr.22837","article-title":"Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis","volume":"68","author":"Mok","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3899\/jrheum.120572","article-title":"The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus","volume":"40","author":"Akhavan","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarcon","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib25","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.rdc.2021.04.012_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2021.04.012_bib27","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1177\/0961203393002001041","article-title":"The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE","volume":"2","author":"Wallace","year":"1993","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.rdc.2021.04.012_bib28","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib29","doi-asserted-by":"crossref","first-page":"576.e7","DOI":"10.1016\/j.ajog.2011.06.064","article-title":"Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression","volume":"205","author":"Wu","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib30","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.rdc.2021.04.012_bib31","first-page":"CD002922","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","volume":"6","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2021.04.012_bib34","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.rdc.2021.04.012_bib35","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.04.012_bib36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"16","key":"10.1016\/j.rdc.2021.04.012_bib37","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJMct1207259","article-title":"Belimumab for systemic lupus erythematosus","volume":"368","author":"Hahn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.rdc.2021.04.012_bib38","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.rdc.2021.04.012_bib39","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.04.012_bib40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A\u00a0phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9767","key":"10.1016\/j.rdc.2021.04.012_bib42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rdc.2021.04.012_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2021.04.012_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.semarthrit.2018.01.001","article-title":"Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus","volume":"48","author":"Oon","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2021.04.012_bib45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib46","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0961203318758505","article-title":"Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis","volume":"27","author":"Choi","year":"2018","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.rdc.2021.04.012_bib47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3109\/14397595.2013.844397","article-title":"Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis","volume":"24","author":"Ikeuchi","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.04.012_bib48","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203313502864","article-title":"Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study","volume":"22","author":"Mok","year":"2013","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2021.04.012_bib51","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2021.04.012_bib52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/1756-185X.12463","article-title":"Current role of rituximab in systemic lupus erythematosus","volume":"18","author":"Mok","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib53","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/rheumatology\/kep124","article-title":"Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?","volume":"48","author":"Li","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2021.04.012_bib54","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfy075","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"33","author":"McAdoo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib55","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2021.04.012_bib56","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.rdc.2021.04.012_bib57","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib59","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/acr.22589","article-title":"Treatment algorithms in systemic lupus erythematosus","volume":"67","author":"Muangchan","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.rdc.2021.04.012_bib60","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0961203317722412","article-title":"Discordance of patient and physician health status concerns in systemic lupus erythematosus","volume":"27","author":"Golder","year":"2018","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.rdc.2021.04.012_bib61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.04.012_bib62","first-page":"455","article-title":"Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis","volume":"13","author":"Bos","year":"2003","journal-title":"Eur J Dermatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib63","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203316641771","article-title":"Advances in the treatment of cutaneous lupus erythematosus","volume":"25","author":"Kuhn","year":"2016","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.rdc.2021.04.012_bib64","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib65","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1634\/theoncologist.2018-0340","article-title":"Evaluation of miracle mouthwash plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: a randomized phase II study","volume":"24","author":"Jones","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semarthrit.2017.11.003","article-title":"Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases","volume":"48","author":"de Risi-Pugliese","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2021.04.012_bib67","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.04.012_bib68","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof MY","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib69","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.39085","article-title":"Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus","volume":"67","author":"Vital","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00281-015-0550-0","article-title":"Lupus erythematosus revisited","volume":"38","author":"Kuhn","year":"2016","journal-title":"Semin immunopathology"},{"issue":"16","key":"10.1016\/j.rdc.2021.04.012_bib71","doi-asserted-by":"crossref","first-page":"e139558","DOI":"10.1172\/jci.insight.139558","article-title":"IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions","volume":"5","author":"Tsoi","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.rdc.2021.04.012_bib72","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib73","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/jid.2015.216","article-title":"Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model","volume":"135","author":"Chan","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib74","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/exd.13253","article-title":"JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus","volume":"26","author":"Klaeschen","year":"2017","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.04.012_bib75","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.berh.2005.04.003","article-title":"Management of neuropsychiatric lupus","volume":"19","author":"Hanly","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.04.012_bib76","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2004.025528","article-title":"Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus","volume":"64","author":"Barile-Fabris","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2021.04.012_bib77","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3899\/jrheum.121096","article-title":"Longterm outcomes and damage accrual in patients with childhood systemic lupus erythematosus with psychosis and severe cognitive dysfunction","volume":"40","author":"Lim","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"13","key":"10.1016\/j.rdc.2021.04.012_bib78","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.rdc.2021.04.012_bib79","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib80","doi-asserted-by":"crossref","first-page":"e000924","DOI":"10.1136\/rmdopen-2019-000924","article-title":"Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"5","author":"Tektonidou","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib82","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2021.04.012_bib83","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.04.012_bib84","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2021.04.012_bib85","doi-asserted-by":"crossref","first-page":"e000274","DOI":"10.1136\/lupus-2018-000274","article-title":"Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres","volume":"5","author":"Tani","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.04.012_bib86","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1572-0241.2006.00524.x","article-title":"Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: a long-term follow-up","volume":"101","author":"Baumgart","year":"2006","journal-title":"Am J Gastroenterol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21000272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21000272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:20:47Z","timestamp":1760181647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X21000272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0889857X21000272"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2021.04.012","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Update in Systemic Lupus Erythematous","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2021.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}